A Study of CDX-622 in Participants With Mild to Moderate Asthma

This study is testing a new drug called CDX-622 in adults with mild to moderate asthma. The drug aims to reduce airway inflammation through a new mechanism, and this study will evaluate whether it is safe and effective at improving asthma control. **You may be eligible if...** - You are 18 or older (male or female) - You have had an asthma diagnosis for at least 12 months - Your baseline lung function (FEV1) is at or above 70% of expected - Your airway responsiveness improves significantly (at least 12% and 200 mL) with a bronchodilator - You are willing to use appropriate contraception during the study and for 150 days after treatment **You may NOT be eligible if...** - You are pregnant or nursing - You have a lung condition other than asthma - You have a condition that causes high eosinophil counts (a type of white blood cell) other than asthma - You were hospitalized or took oral steroids for asthma in the past 6 months - You have ever needed a ventilator for asthma - You have current nasal polyps, severe/uncontrolled asthma, tuberculosis, hepatitis B or C, or HIV - You have smoked or vaped in the past 12 months - You have received immune-modulating drugs or prior TSLP/KIT inhibitor treatments such as tezepelumab Talk to your doctor to see if this trial is right for you.